Ariad begins Phase 2 trial of Iclusig to treat GI tumors
June 11, 2013 at 13:56 PM EDT
Ariad Pharmaceuticals, Inc. (Nasdaq: ARIA) has launched a Phase 2 trial to test its approved leukemia drug Iclusig as a potential treatment for gastrointestinal stromal tumors (GIST)...
